McGuireKFungLKHagopianL, et al. Irritability and problem behavior in autism spectrum disorder: a practice pathway for pediatric primary care. Pediatrics. 2016;137(suppl 2):S136-S148. doi:10.1542/peds.2015-2851l.
2.
CianfaglioneRClarkeAKerrM, et al. A national survey of Rett syndrome: behavioural characteristics. J Neurodev Disord. 2015;7(1):11. doi:10.1186/s11689-015-9104-y.
3.
SinghJSantoshP.Key issues in Rett syndrome: emotional, behavioural and autonomic dysregulation (EBAD)—a target for clinical trials. Orphanet J Rare Dis. 2018;13(1):128. doi:10.1186/s13023-018-0873-8.
4.
BuchananCBStallworthJLJoyAE, et al. Anxiety-like behavior and anxiolytic treatment in the Rett syndrome natural history study. J Neurodev Disord. 2022;14(1):31. doi:10.1186/s11689-022-09432-2.
5.
SinghJLanzariniENardocciNSantoshP.Movement disorders in patients with Rett syndrome: a systematic review of evidence and associated clinical considerations. Psychiatry Clin Neurosci. 2021;75(12):369-393. doi:10.1111/pcn.13299.
6.
HoffmannJAPergjikaAKonicekCEReynoldsSL.Pharmacologic management of acute agitation in youth in the emergency department. Pediatr Emerg Care. 2021;37(8):417-422. doi:10.1097/PEC.0000000000002510.
7.
NeulJLPercyAKBenkeTA, et al. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. Contemp Clin Trials. 2022;114:106704. doi:10.1016/j.cct.2022.106704.
8.
SabusAFeinsteinJRomaniPGoldsonEBlackmerA.Management of self-injurious behaviors in children with neurodevelopmental disorders: a pharmacotherapy overview. Pharmacotherapy. 2019;39(6):645-664. doi:10.1002/phar.2238.
